Henry Meds Pricing History and Trajectory: What You'll Actually Pay Over Time

How Henry Meds Built Its Pricing Model

Henry Meds entered the telehealth GLP-1 market in 2022 with a cash-pay, membership-based model designed to undercut brand-name semaglutide. The structure bundles provider consultations, asynchronous messaging, and compounded medication into one flat monthly charge. No insurance is accepted, and no insurance is required.

That bundling was intentional. By eliminating insurance billing overhead, the company could advertise a single number rather than separate drug costs, copays, and visit fees. For patients facing $1,200 to $1,400 per month for brand-name Wegovy (semaglutide 2.4 mg, Novo Nordisk) without coverage, the value proposition was immediate.

The 503A vs. 503B Compounding Distinction

Henry Meds works with both 503A patient-specific compounding pharmacies and, in some cases, 503B outsourcing facilities. The distinction matters for pricing and oversight. Under 21 U.S.C. § 503A, a 503A pharmacy compounds for an individual patient prescription. Under 21 U.S.C. § 503B, a 503B outsourcing facility can produce larger batches but faces more stringent FDA inspection requirements.

Compounded semaglutide was legally permissible during the period when FDA listed semaglutide injections on its drug shortage database. That listing was the legal hook. Once FDA removed Ozempic and Wegovy from the shortage list in March and late 2024 respectively, that hook became unstable for 503B facilities first, then for 503A pharmacies facing a compliance deadline.

Why Cash-Pay Compounding Attracted Patients

Branded semaglutide remains out of reach for most uninsured or underinsured patients. The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (Wilding et al., NEJM 2021). That magnitude of efficacy created enormous patient demand that insurance coverage lagged years behind.

Henry Meds, alongside competitors like Hims & Hers and Found, positioned compounded semaglutide as the accessible alternative. The pricing competition that followed drove costs down across the sector between 2023 and 2025.

A Year-by-Year Look at Henry Meds Pricing

Reconstructing pricing history for a private telehealth company requires cross-referencing archived web pages, consumer forums, complaint filings, and independent reporting. Henry Meds does not publish a formal pricing history document. The figures below reflect the best available public record.

2022: Launch Pricing

Henry Meds began offering compounded semaglutide at approximately $297 per month. This price covered the titration doses typically used in the first 2 to 3 months of therapy (0.25 mg and 0.5 mg weekly injections), consultation, and ongoing messaging support.

At launch, this was among the lowest advertised prices in the direct-to-consumer telehealth GLP-1 space. Competitors were still primarily selling brand-name products through insurance channels or charging $400 or more monthly for compounded alternatives.

2023: Price Reduction and Tirzepatide Addition

Increased competition through 2023 pushed Henry Meds to reduce its semaglutide pricing. By mid-2023, multiple consumer reports and archived pricing pages indicate the entry-level monthly charge dropped to approximately $247 per month for lower titration doses. The higher maintenance doses (1.7 mg and 2.4 mg weekly) carried separate, higher price tiers, though exact figures varied by pharmacy partner and state.

Henry Meds added compounded tirzepatide (the active ingredient in Eli Lilly's Mounjaro and Zepbound) to its formulary in late 2023. Tirzepatide pricing launched at approximately $349 to $449 per month depending on dose. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight reduction at 72 weeks versus 3.1% placebo (Jastreboff et al., NEJM 2022), giving the company strong clinical data to market around.

2024: Competitive Floor and Dose-Tiered Pricing

By 2024, the compounded GLP-1 market had become crowded. At least a dozen telehealth companies offered compounded semaglutide, and price competition pushed Henry Meds to introduce more transparent dose-based tiers. Consumer-reported pricing from 2024 shows:

• Semaglutide starter tier (0.25 mg weekly): approximately $197/month
• Semaglutide mid-dose (0.5 mg to 1 mg weekly): approximately $247/month
• Semaglutide maintenance (1.7 mg to 2.4 mg weekly): approximately $297, $347/month
• Tirzepatide standard dose: approximately $349, $449/month

These figures are based on consumer reviews and archived pricing pages. Henry Meds has not independently verified them to HealthRX, and prices vary by state and pharmacy partner.

2025: Regulatory Headwinds and Price Uncertainty

The FDA formally removed semaglutide injections from its shortage database in early 2025, then issued guidance giving 503B outsourcing facilities until a specified deadline to stop compounding. For 503A pharmacies, a separate compliance timeline applies. FDA's March 2025 guidance document clarified that compounding of commercially available drug products is impermissible once shortage status ends, except under narrow circumstances.

Henry Meds publicly stated it was monitoring the regulatory situation and transitioning patients where necessary. As of mid-2025, the company continues to advertise compounded semaglutide in some states while messaging about potential formulary shifts. Pricing in this environment is volatile and subject to change without the notice patients expect.

Is Henry Meds Legit?

Henry Meds is a licensed telehealth company. Its providers are licensed physicians or nurse practitioners in the states where it operates. The pharmacies it partners with are licensed by the relevant state boards of pharmacy. Those baseline facts make it a legal operation.

"Legit" and "without risk" are not the same thing.

Licensing and Regulatory Standing

Henry Meds operates under the standard telehealth model: a medical practice entity (or affiliated entity) employs or contracts with licensed prescribers, who conduct asynchronous or synchronous consultations and issue prescriptions to state-licensed compounding pharmacies. This model is legal in states that permit asynchronous prescribing for weight management.

The FDA's oversight concern is not the company's telehealth license. The concern is whether the compounding pharmacies it works with are following federal law governing compounded drug products. FDA has issued warning letters to multiple 503B compounding pharmacies over GLP-1 products in 2024 and 2025 (see FDA's Warning Letters database).

BBB Complaints and Consumer Feedback

Henry Meds is not accredited by the Better Business Bureau as of mid-2025. Its BBB profile lists a pattern of consumer complaints, many centering on:

• Difficulty canceling subscriptions after the first charge
• Charges continuing after cancellation requests were submitted
• Delays in medication shipment without proactive communication
• Customer service response times described as slow or inadequate

These complaint patterns are not unique to Henry Meds. They appear across multiple compounded GLP-1 telehealth companies and reflect a broader industry issue with subscription billing practices. Patients should document all cancellation requests in writing and monitor their payment method after requesting cancellation.

LegitScript Certification

LegitScript, a third-party verification service that assesses online pharmacy compliance, has not publicly listed Henry Meds as a certified telehealth provider as of this writing. LegitScript certification requires compliance with applicable pharmacy laws, valid prescriptions, and licensed pharmacy operations. Its absence does not prove illegality, but its presence would provide additional assurance. Patients can check current status at legitscript.com.

A Framework for Evaluating Compounded GLP-1 Telehealth Companies

Before committing to any compounded GLP-1 subscription, patients should ask five specific questions:

1. Which compounding pharmacy fills my prescription, and can I verify its state license and any FDA inspection history?
2. Does the company use a 503A or 503B pharmacy, and does that distinction affect my legal access to the medication if shortage status ends?
3. What is the exact cancellation policy, and will I receive written confirmation of cancellation with a date-stamped record?
4. Are the prescribing providers licensed in my state, and can I obtain their license numbers independently?
5. How will the company notify me if FDA enforcement actions require a formulary change, and what happens to my subscription fee if the medication becomes unavailable?

Henry Meds, like its competitors, does not prominently answer all five of these questions in its onboarding flow. Patients need to ask directly before subscribing.

Henry Meds Complaints: What Patterns Emerge

Complaint data from the BBB, Trustpilot, and Reddit's r/Semaglutide and r/WeightLossAdvice communities reveals consistent themes. Across several hundred consumer-generated reviews and formal complaints reviewed for this article, the most frequent issues fall into three categories.

Billing and Subscription Disputes

Subscription cancellation difficulties account for the largest share of reported complaints. Patients report being charged after submitting cancellation requests through the patient portal, with some reporting 2 to 3 additional billing cycles before charges stopped. Henry Meds' stated terms indicate that cancellations must be received a set number of days before the next billing date, and that dispensed medication is non-refundable.

The FTC's Negative Option Rule, updated in 2024, requires that subscription cancellation be as simple as enrollment. Patients experiencing billing disputes may file complaints with the FTC at ftc.gov/complaint.

Medication Delays and Pharmacy Transitions

Multiple patients report delays of 2 to 4 weeks between prescription approval and medication arrival, particularly during periods when Henry Meds switched pharmacy partners. These transitions appear to have occurred at least twice between 2023 and 2025, and they were not always communicated proactively to affected patients.

Medication delays are not trivial for patients on dose titration schedules. Missing a weekly injection due to supply delays can disrupt the titration protocol recommended in the Wegovy prescribing information (FDA label, semaglutide injection 2.4 mg), which calls for weekly consistent dosing to minimize gastrointestinal side effects.

Provider Communication Quality

A smaller but consistent complaint category involves provider accessibility. Asynchronous telehealth models, by design, do not provide immediate provider contact. Patients report that responses to clinical questions sometimes took 48 to 72 hours, and that follow-up after side effect reports was variable.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that "patients receiving GLP-1 receptor agonist therapy should receive structured follow-up at 12 weeks to assess tolerability and dose appropriateness" (Endocrine Society, 2023). An asynchronous model can meet that standard, but only if the platform actively prompts structured check-ins rather than relying on patients to initiate contact.

The Regulatory Horizon and What It Means for Pricing

The FDA's position on compounded semaglutide has shifted materially since 2024, and the trajectory points toward tighter restrictions. The agency's April 2024 statement on compounding of GLP-1 drugs made clear that once a drug is no longer in shortage, bulk compounding is not automatically permissible.

For 503B facilities, the deadline to stop producing compounded semaglutide passed in spring 2025. For 503A pharmacies, a separate litigation track extended compounding permissions temporarily for individually prescribed preparations, but that status remains subject to ongoing court proceedings as of publication.

What Happens to Monthly Pricing If Compounding Ends

If FDA enforcement ultimately forecloses compounded semaglutide, Henry Meds and similar platforms face a fundamental business model question. The remaining options are:

• Transition to branded semaglutide (Wegovy or Ozempic) and assist patients with manufacturer savings programs. Novo Nordisk's WeightLoss.com savings card brings Wegovy to roughly $499/month for cash-pay patients without insurance.
• Pivot to other compounded or FDA-approved weight-loss agents (bupropion/naltrexone, phentermine/topiramate, oral semaglutide pending availability).
• Exit the GLP-1 category entirely.

None of these paths maintains current Henry Meds pricing levels. Patients who have built their weight-loss plans around a $197 to $247 monthly cost should plan for potential price discontinuity.

The Cost of Untreated Obesity

This pricing discussion exists in a clinical context that matters. Obesity affects approximately 41.9% of U.S. Adults (CDC, 2023). The direct medical costs associated with obesity-related conditions, including type 2 diabetes, hypertension, and obstructive sleep apnea, add an estimated $1,861 per year in excess medical spending per individual with obesity versus a person with a healthy weight (Cawley and Meyerhoefer, American Journal of Health Economics, 2012). Access to affordable GLP-1 therapy is a public health issue, not merely a consumer pricing question.

How Henry Meds Compares to Key Competitors on Price

Pricing comparisons across compounded GLP-1 telehealth companies are difficult because prices change frequently and dose tiers differ. The table below reflects best-available mid-2025 data.

| Company | Compounded Semaglutide (starter) | Compounded Tirzepatide (standard) | BBB Accredited | |---|---|---|---| | Henry Meds | ~$197/month | ~$349, $449/month | No | | Hims & Hers | ~$199/month | ~$299, $399/month | No | | Found | ~$99/month (medication only, separate membership fee) | Not listed | No | | Ro Body | ~$199/month | ~$449/month | No | | LifeMD | ~$249/month | ~$399, $499/month | Yes |

No compounded GLP-1 telehealth company in this comparison holds current BBB accreditation. That absence reflects an industry-wide pattern rather than a Henry Meds-specific deficiency. Patients should treat BBB accreditation as one data point among several, not a pass-fail screen.

What Patients Should Know Before Subscribing

Henry Meds is one of several plausible options for patients seeking affordable compounded semaglutide or tirzepatide. Its pricing history shows responsiveness to market competition and a track record of reducing costs over time. Its complaint history shows real friction in billing and communication that prospective patients should account for.

The central question for anyone considering Henry Meds in mid-2025 is not price. The question is whether the regulatory pathway for compounded semaglutide will remain open long enough to justify starting or continuing therapy through this channel.

Patients already seeing results on compounded semaglutide should discuss with their prescriber what a transition to branded Wegovy or another agent would look like, and whether manufacturer co-pay assistance programs (Novo Nordisk's patient assistance program) could bridge a pricing gap.

Patients starting fresh should ask Henry Meds directly, in writing, how it will handle their subscription and billing if FDA enforcement requires it to discontinue compounded semaglutide in their state. The answer, or the absence of one, is informative.

The FDA's 2024 statement on compounded GLP-1 products says explicitly that "FDA cannot assure the safety, effectiveness, or quality of compounded drugs" and that patients should be aware compounded drugs "have not been approved by FDA." (FDA, 2024). That statement does not mean compounded semaglutide is dangerous. It means patients take on additional uncertainty compared to using an FDA-approved product.

At your next telehealth visit, ask your provider for the name and NABP number of the specific compounding pharmacy dispensing your medication, then verify that pharmacy's license status independently at nabp.pharmacy.